Literature DB >> 27343100

Hypoxic Adaptation in the Nervous System: Promise for Novel Therapeutics for Acute and Chronic Neurodegeneration.

Rachel Speer1,2, Rajiv R Ratan3,4.   

Abstract

Homeostasis is the process by which cells adapt to stress and prevent or repair injury. Unique programs have evolved to sense and activate these homeostatic mechanisms and as such, homeostatic sensors may be potent therapeutic targets. The hypoxic response mediated by hypoxia inducible factor (HIF) downstream of oxygen sensing by HIF prolyl 4-hydroxylases (PHDs) has been well-studied, revealing cell-type specific regulation of HIF stability, activity, and transcriptional targets. HIF's paradoxical roles in nervous system development, physiology, and pathology arise from its complex roles in hypoxic adaptation and normoxic biology. Understanding how to engage the hypoxic response so as to recapitulate the protective mechanism of ischemic preconditioning is a high priority. Indeed, small molecules that activate the hypoxic response provide broad neuroprotection in several clinically relevant injury models. Screens for PHD inhibitors have identified novel therapeutics for neuroprotection that are ready to proceed to clinical trials for ischemic stroke. Better understanding the mechanisms of how to engage hypoxic adaption without altering development or physiology may identify additional novel therapeutic targets for diverse acute and chronic neuropathologies.

Entities:  

Keywords:  HIF; Hypoxia sensing; Prolyl hydroxylase; Stroke

Mesh:

Substances:

Year:  2016        PMID: 27343100     DOI: 10.1007/978-1-4899-7678-9_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors.

Authors:  Irina N Gaisina; Sue H Lee; Navneet A Kaidery; Manel Ben Aissa; Manuj Ahuja; Natalya N Smirnova; Sushama Wakade; Arsen Gaisin; Megan W Bourassa; Rajiv R Ratan; Sergey V Nikulin; Andrey A Poloznikov; Bobby Thomas; Gregory R J Thatcher; Irina G Gazaryan
Journal:  ACS Chem Neurosci       Date:  2018-01-17       Impact factor: 4.418

2.  Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis.

Authors:  Carlos R Camara-Lemarroy; Luanne Metz; Eric E Smith; Jeff F Dunn; V Wee Yong
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

3.  Effect of Intrahippocampal Administration of α7 Subtype Nicotinic Receptor Agonist PNU-282987 and Its Solvent Dimethyl Sulfoxide on the Efficiency of Hypoxic Preconditioning in Rats.

Authors:  Elena I Zakharova; Andrey T Proshin; Mikhail Y Monakov; Alexander M Dudchenko
Journal:  Molecules       Date:  2021-12-06       Impact factor: 4.411

4.  Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).

Authors:  Pedro Soares; Morgan S Gadd; Julianty Frost; Carles Galdeano; Lucy Ellis; Ola Epemolu; Sonia Rocha; Kevin D Read; Alessio Ciulli
Journal:  J Med Chem       Date:  2017-09-18       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.